This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that a combination of Bavencio (avelumab) and Inlyta (axitinib) be approved for the first-line treatment of adults with advanced renal cell carcinoma, the most common form of kidney cancer.…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
For Breast Cancer Awareness Month, Life Image Offering Free Access to Mammosphere App
This post was originally published on this site Because access to prior mammograms is critical for women during all stages of breast health, Life Image is offering free membership during October — Breast Cancer Awareness Month — to its unique health management platform. At the same time, the global network for sharing clinical and imaging…
Nonspecific Symptoms Lead to Lower Quality of Life for Patients, Partners, Study Shows
This post was originally published on this site Sarcoidosis patients and their partners experience a lower quality of life because of nonspecific disease-associated symptoms compared to healthy people, a new study demonstrated. The study, titled “Quality of Life of Couples Living with Sarcoidosis,” was published in the journal Respiration. Sarcoidosis is an inflammatory disease affecting…
Fate Therapeutics Plans Trials Testing Off-the-shelf NK Cell Therapy for Lymphoma, Leukemia
This post was originally published on this site Fate Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to initiate clinical studies evaluating FT596, its off-the-shelf cell-based immunotherapy designed to target multiple tumor proteins. The company plans to start testing FT596 for the treatment of B-cell lymphoma and chronic lymphocytic leukemia, either…
Ilixadencel-Sutent Combo Shows Efficacy in Advanced Kidney Cancer, Phase 2 Trial Reports
This post was originally published on this site A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 trial. Ilixadencel, Immunicum‘s lead candidate for the treatment of different types of solid tumors, is a cancer…
Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says
This post was originally published on this site Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt for active surveillance, a study found. Among 547 men who choose active surveillance, only two experienced tumor progression…
ENGAGe and ESGO Present First World Gynecologic Oncology Day
This post was originally published on this site On Sept. 20, the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and the European Society of Gynaecological Oncology (ESGO) presented the first World Gynecologic Oncology Day (World GO Day). Spearheaded by ENGAGe, the initiative, set to occur annually, aims to promote collaboration among patient groups, strengthen…
Darzalex Combo Increases Response Rates in Newly Diagnosed Multiple Myeloma Patients, Trial Shows
This post was originally published on this site Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases the proportion of people with multiple myeloma who experience a decrease in tumor burden, a Phase 2 trial shows. The results occurred among newly diagnosed patients eligible…
New Herceptin-Perjeta Formulation Shows Promising Safety and Pharmacokinetic Profile, Phase 3 Trial Shows
This post was originally published on this site When given together with Herceptin (trastuzumab) at a fixed dose through an under-the-skin (subcutaneous) injection, Perjeta (pertuzumab) reaches levels in the blood in women with HER2-positive breast cancer that is similar to those seen when the medication is administered intravenously, data from a Phase 3 trial shows.…
Pain Takes Significant Toll on Ovarian Cancer Survival, Study Shows
This post was originally published on this site For the first time, scientists have found evidence that pain is an independent marker for overall survival in recurrent ovarian cancer, with women with pain living for significantly less time after their diagnosis than those without pain. The survival toll is particularly high for patients with pain…
Investigational Antibody GBR 1342 Receives Orphan Drug Designation for Multiple Myeloma
This post was originally published on this site GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma patients who have received prior therapies. The FDA’s Office of Orphan Products Development (OOPD) gives this designation to novel…
‘Be Bold, Be Bald!’ Day for Cancer Organizations Set for Oct. 18
This post was originally published on this site In solidarity with cancer patients, including those with lymphoma, thousands of people throughout the U.S. are expected to sport bald caps Oct. 18 as part of an annual effort called “Be Bold, Be Bald!” to raise funds and awareness. The event — held every year on the…